Tiziana Life Sciences Ltd
TLSA
$1.18
$0.054.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -25.99% | -25.99% | 51.18% | 51.18% | 48.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.63% | 28.63% | 41.17% | 41.17% | -0.05% |
| Operating Income | -28.63% | -28.63% | -41.17% | -41.17% | 0.05% |
| Income Before Tax | -46.01% | -46.01% | 29.42% | 29.42% | -1.63% |
| Income Tax Expenses | -- | -- | -- | -- | -446.77% |
| Earnings from Continuing Operations | -77.54% | -77.54% | -21.01% | -21.01% | 20.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -77.54% | -77.54% | -21.01% | -21.01% | 20.55% |
| EBIT | -28.63% | -28.63% | -41.17% | -41.17% | 0.05% |
| EBITDA | -28.61% | -28.61% | -41.27% | -41.27% | 0.06% |
| EPS Basic | -63.30% | -63.30% | -6.64% | -6.64% | 26.02% |
| Normalized Basic EPS | -33.74% | -33.74% | -19.59% | -19.59% | 2.02% |
| EPS Diluted | -63.30% | -63.30% | -6.64% | -6.64% | 26.02% |
| Normalized Diluted EPS | -33.74% | -33.74% | -19.59% | -19.59% | 2.02% |
| Average Basic Shares Outstanding | 8.61% | 8.61% | 13.32% | 13.32% | 7.38% |
| Average Diluted Shares Outstanding | 8.61% | 8.61% | 13.32% | 13.32% | 7.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |